Teva and Samsung Bioepis Enter into an Agreement to Commercialize Two FDA-Approved Biosimilars in the US

Shots: Teva & Samsung Bioepis have entered a license & commercialization agreement for 2 FDA-approved immunology biosimilars in the US: infliximab-abda (biosimilar to Remicade) & ETICOVO (etanercept-ykro; biosimilar to Enbrel) Teva will gain US commercialization rights to etanercept-ykro at closing & to infliximab-abda in Q3’27, while Samsung Bioepis remains responsible for regulatory oversight & manufacturing; closing is anticipated by the end of 2026 Samsung Bioepis will receive an upfront payment over 3yrs. & may be eligible for launch & sales milestones, with both companies sharing profits; the deal expands their existing biosimilar collaborations Ref: GlobeNewswire  |   Image: Teva  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Teva and Samsung Bioepis Enter into an Agreement to Commercialize Two FDA-Approved Biosimilars in the US appeared first on PharmaShots.